Platelet antibody screening and crossmatch in Chengdu in 2019
10.13303/j.cjbt.issn.1004-549x.2021.04.014
- VernacularTitle:血小板抗体筛查及交叉配型的临床应用
- Author:
Xixi TAN
1
;
Xiwei WEI
1
;
Tianxiang GONG
1
;
Ying HONG
1
;
Zhiru LI
1
;
Meng LI
1
;
Xuemei FU
1
;
Shuping LI
1
Author Information
1. Chengdu Blood Center, Chengdu 610041, China
- Publication Type:Journal Article
- Keywords:
platelet antibody screening;
platelet crossmatch;
platelet transfusion refractoriness
- From:
Chinese Journal of Blood Transfusion
2021;34(4):382-385
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To analyze the status of the platelet antibody screening and crossmatch in Chengdu in 2019, so as to further improve the corresponding detection strategy to improve the clinical transfusion efficacy. 【Methods】 The patients underwent platelet antibody crossmatch in Chengdu Blood Center in 2019 were selected as research objects Platelet antibody screening and crossmatch were performed by solid-phase agglutination technique, and the sample size, the incidence of platelet antibod, age, blood group, seasonal chracteristics, hospital levels, ratio of repeated crossmatch and the transfusion efficacy were analyzed. 【Results】 321 treatment doses of matched platelets after 259 occasions of crossmatch relative to 85 patients were provided. The positive rate of platelet antibody was 87.06%. 64.71% of the patients were over 40 years old, the proportion of ABO group in crossmatch samples was O>A>B>AB, and the crossmatch cases increased each quarter gradually. All samples were provided by tertiary hospitals. 52.94% of the patients needed crossmatch at least twice, and the efficacy rate of matched platelets transfusion was 63.64%. 【Conclusion】 The platelet transfusion efficacy could by improved by platelet antibody screening and crossmatch, so as to avoid the waste of platelets, which deserves active promotion in clinical.
